News

Cytori Therapeutics, Inc., a company developing autologous ADRCs-based cell therapies for the treatment of several conditions, including scleroderma, has been granted conditional approval by the U.S. Food and Drug Administration (FDA), for an Investigational Device Exemption (IDE) for their investigational scleroderma therapy. The pivotal trial, dubbed “STAR,” aims to evaluate the potential of Cytori Cell Therapy,…

Biopharmaceutical company Apricus Biosciences, Inc. announced it has successfully enrolled the first patient for a Phase 2a clinical trial for RayVa™, the company’s frontline candidate for scleroderma-related Raynaud’s phenomenon. Scleroderma, classified among autoimmune rheumatic diseases, causes hardening or spontaneous scarring of the skin, internal organs,…

The American College of Rheumatology (ACR), together with the European League Against Rheumatism (EULAR) published new criteria for classification of systemic sclerosis. The new guidelines were introduced to allow earlier diagnosis and facilitate more targeted therapeutic treatments. The criteria were published in the journal of Arthritis & Rheumatism in…

New Scleroderma-related findings have linked two variations of the disease, which in turn could lead to effective, new biomarkers and targeted treatments for patients. Two clinically different diseases, localized scleroderma (LS) and systemic sclerosis (SSc), can be characterized by similar T-cell produced cytokines and chemokines in pediatric patients,…

A group from Massachusetts General Hospital is placing possible blame for systemic sclerosis (SSc) pathogenesis on autotaxin (ATX), an enzyme involved in the production of the lipid signaling molecule lysophophatidic acid (LPA). Dr. Falvia V. Castelino, a researcher in the Rheumatology Department, presented the group’s work, “…

Federal University of São Paulo recently initiated a phase 3 clinical trial evaluating the use of probiotics in patients with systemic sclerosis (SSc) to determine the efficacy and safety of treating gastrointestinal symptoms of SSc. As an autoimmune disease, SSc may benefit from probiotics due to their ability to…

The Chief Executive Officer of emerging growth drug development company Corbus Pharmaceuticals Holdings, Inc. has been invited to present at the Virtual Investor Conferences, a live and interactive online event that will take place on Thursday, December 4 at 11:30 a.m. EST. Yuval Cohen, Ph.D., CEO of Corbus,…

At times, a major roadblock to conducting clinical trials is enrolling enough patients to fill a study for appropriate data analyses. This may not be the case for studies involving patients with juvenile localized scleroderma (jLS), according to a study from Hackensack University Medical Center. The study, led by…

Researchers at the Centre for Rheumatology and Connective Tissue Disease at University College London have found new evidence that could help in understanding how lung blood vessel disease (pulmonary vasculopathy) in systemic sclerosis develops. The study could form the basis for future treatments that block the condition from occurring. The work…

Recently, autologous haematopoietic stem cell transplantation (AHSCT) has become more popular in treating patients with systemic sclerosis (SSc). Canadian SSc patients have actually been seeking out experimental AHSCT treatments in the United States to aid their…